Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf; Hong Zhang; Carlos H. Barrios; Shigehira Saji; Kyung Hae Jung; Roberto Hegg; Andreas Koehler; Joohyuk Sohn; Hiroji Iwata; Melinda L. Telli; Cristiano Ferrario; Kevin Punie; Frédérique Penault-Llorca; Shilpen Patel; Anh Nguyen Duc; Mario Liste-Hermoso; Vidya Maiya; Luciana Molinero; Jane Yuet Ching Hui; Nadia Harbeck

doi:10.1016/s0140-6736(20)31953-x

Keywords

MedicineAtezolizumabAnthracyclineOncologyChemotherapyInternal medicinePlaceboNab-paclitaxelBreast cancerTriple-negative breast cancerPaclitaxelStage (stratigraphy)CancerImmunotherapyPembrolizumabPathology

Affiliated Institutions

Related Publications

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid , Javier Cortés , Lajos Pusztai +18 more

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...

2020 New England Journal of Medicine 2718 citations

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid , Hope S. Rugo , Sylvia Adams +12 more

2019 The Lancet Oncology 1134 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2020
Type: article
Volume: 396
Issue: 10257
Pages: 1090-1100
Citations: 989
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

989

OpenAlex

Cite This

APA Style

                            
                                
                                    Elizabeth A. Mittendorf, 
                                
                                    Hong Zhang, 
                                
                                    Carlos H. Barrios
                                
                                et al.
                            
                            (2020). 
                            Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. 
                            The Lancet
                            , 396
                            (10257)
                            , 1090-1100.
                            https://doi.org/10.1016/s0140-6736(20)31953-x
                        

Identifiers

DOI: 10.1016/s0140-6736(20)31953-x